Teva Pharmaceuticals

Why Generic Drug Prices Are Dropping
Why Generic Drug Prices Are DroppingPharmacy chains are forcing lower generic prices for their customers.
Paliperidone and Clindamycin Recalls
FDA approves first generic Truvada for HIVThe first generic Truvada for treating and preventing HIV will be available, but when?
Novel drug approved for Huntington's symptomFDA recently approved deutetrabenazine (Austedo, Teva Pharmaceuticals) to treat chorea associated with Huntington’s disease (HD). The medication is only the second product approved to treat HD, and is the first deuterated product approved by FDA.
Generic versions of major depression drug availableMylan received approval from FDA to market its desvenlafaxine extended-release tablets, the generic version of Pristiq (Pfizer), for major depressive disorder. Plus, 2 other manufacturers recently received approval for their generic versions of Pristiq.
Teva halts migraine patch sales over burnsTeva Pharmaceuticals is temporarily suspending sales and distribution of its sumatriptan iontophoretic transdermal system (Zecuity) patch for migraines, after FDA said it is investigating the risk of serious burns with the use of the patch.
5 facts to know about the new asthma drugFDA recently approved reslizumab (Cinqair, Teva Pharmaceuticals), an injectable used with other asthma medicines for the maintenance treatment of severe asthma. Here are the top 5 facts to know about Cinqair.
Why generic Viagra will have to waitWhile FDA just approved the first generic version of sildenafil citrate (Viagra, Pfizer), the new product won’t be on the market until late 2017.
Pfizer makes huge multimillion-dollar Medicaid settlementIn one of the biggest drug pricing settlements in history, Pfizer is paying $784.6 million to settle claims alleging that the practices of its Wyeth subsidiary relating to the calculation of Medicaid rebates for Protonix (pantoprazole sodium) violated the Federal Civil False Claims Act and other laws.
First generic MS drug could have big impactFDA’s approval of the first generic version of Copaxone for treating patients with relapsing forms of multiple sclerosis has industry insiders contemplating the impact on the generics market as well as payer coverage strategies.